NASDAQ · MAZE
Healthcare · Biotechnology
$30.37
Down-$1.11 (-3.53%)
Updated Nov 3, 2026, 12:52 PM
SID Score
4.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · MAZE
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 2, 2026
MAZE closed at $30.37 after 21 trading sessions, up 14.91% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 2, 2026 | $31.70 | $31.70 | $29.75 | $30.37 | 331.7K |
| Oct 30, 2026 | $31.93 | $32.46 | $31.23 | $31.48 | 327.13K |
| Oct 29, 2026 | $32.17 | $32.63 | $31.56 | $31.93 | 417.92K |
| Oct 28, 2026 | $31.24 | $32.085 | $30.89 | $31.73 | 390.83K |
| Oct 27, 2026 | $31.18 | $32.01 | $30.88 | $31.69 | 624.99K |
| Oct 26, 2026 | $30.93 | $31.665 | $30.706 | $31.07 | 429.42K |
| Oct 23, 2026 | $31.86 | $31.86 | $30.54 | $31.01 | 512.94K |
| Oct 22, 2026 | $32.45 | $32.95 | $31.71 | $31.95 | 891.55K |
| Oct 21, 2026 | $32.52 | $33.185 | $31.555 | $32.58 | 1.07M |
| Oct 20, 2026 | $29.82 | $32.61 | $29.581 | $32.45 | 1.57M |
| Oct 19, 2026 | $28.01 | $30.57 | $27.83 | $29.70 | 1.3M |
| Oct 16, 2026 | $27.50 | $27.89 | $26.72 | $27.53 | 1.02M |
| Oct 15, 2026 | $26.59 | $28.105 | $26.46 | $27.48 | 540.02K |
| Oct 14, 2026 | $26.51 | $27.085 | $25.965 | $26.23 | 835.7K |
| Oct 13, 2026 | $27.54 | $28.24 | $26.57 | $26.66 | 615.15K |
| Oct 12, 2026 | $27.11 | $29.32 | $26.662 | $27.70 | 1.44M |
| Oct 9, 2026 | $25.88 | $27.19 | $25.88 | $27.11 | 670.93K |
| Oct 8, 2026 | $25.97 | $26.44 | $25.05 | $25.88 | 903K |
| Oct 7, 2026 | $26.30 | $26.885 | $25.87 | $26.25 | 823.9K |
| Oct 6, 2026 | $26.74 | $26.91 | $25.785 | $26.43 | 682.84K |
| Oct 5, 2026 | $26.67 | $27.03 | $25.78 | $26.43 | 588.01K |
The latest Smart Investors Daily articles mentioning MAZE.
Company
Market Activity
Research & News
MAZE research
Company profile and research snapshot.
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 19, 2026 | Canaccord Genuity | Buy | — |
| Sep 24, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 23, 2026 | Citigroup | Buy | — |
| Sep 23, 2026 | Wedbush | Outperform | — |
| Sep 22, 2026 | BTIG | Buy | — |
No generated briefing is available yet.
Yahoo · Oct 19, 2026
Maze Therapeutics, Inc. (MAZE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Yahoo · Oct 19, 2026
The average of price targets set by Wall Street analysts indicates a potential upside of 123.4% in Maze Therapeutics, Inc. (MAZE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Benzinga · Oct 19, 2026
Canaccord Genuity analyst Whitney Ijem initiates coverage on Maze Therapeutics (NASDAQ:MAZE) with a Buy rating and announces Price Target of $75.
Yahoo · Oct 13, 2026
Recently published Pompe Disease Market Insights report includes a comprehensive understanding of current treatment practices, Pompe disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning MAZE.
